

Filed On Behalf Of:

Alkermes Pharma Ireland Limited and
Alkermes Controlled Therapeutics, Inc.

By:

Scott K. Reed
sreed@fchs.com
212-218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

LUYE PHARMA GROUP LTD., LUYE PHARMA(USA) LTD., SHANDONG
LUYE PHARMACEUTICAL CO., LTD., and NANJING LUYE
PHARMACEUTICAL CO., LTD.,
Petitioners,

v.

ALKERMES PHARMA IRELAND LTD,
Patent Owner.

Case IPR2016-01096
Patent 6,667,061

**PATENT OWNERS' AMENDED MANDATORY NOTICES
UNDER 37 C.F.R. § 42.8(a)(3)**

Pursuant to 37 C.F.R. § 42.8(a)(3), Alkermes Pharma Ireland Limited and Alkermes Controlled Therapeutics, Inc. (hereinafter, collectively “Patent Owners”) submits the following amended information to its June 21, 2016 Mandatory Notices (Paper No. 9).

REAL PARTY-IN-INTEREST PURSUANT TO 37 C.F.R. § 42.8(b)(1)

Pursuant to the requirements of 37 C.F.R. § 42.8(a)(3), Patent Owner states that the address for Amylin Pharmaceuticals, LLC has been updated. The current address for Amylin Pharmaceuticals, LLC is:

1800 Concord Pike
Wilmington, DE
19850.

Respectfully submitted,

Dated: June 30, 2016

/Scott K. Reed /
Scott K. Reed
Registration No. 32,433
Lead Counsel for Patent Owners
FITZPATRICK, CELLA, HARPER
& SCINTO
1290 Avenue of the Americas
New York, NY 10104-3800
Tel. 212-218-2100

CERTIFICATE OF SERVICE

I certify that a copy of the Patent Owners' Amended Mandatory Notices Under 37 C.F.R. § 42.8(a)(3) was served on June 30, 2016 by causing it to be sent by email to counsel for Petitioners at the following email address, who consented to electronic service at these addresses in the Petition:

wmentlik.ipr@lerner david.com

pkochanski@lerner david.com

tvanbuskirk@lerner david.com

nvaleyko@lerner david.com

Dated: June 30, 2016

/Scott K. Reed /

Scott K. Reed

Registration No. 32,433

Lead Counsel for Patent Owners

FITZPATRICK, CELLA, HARPER
& SCINTO

1290 Avenue of the Americas

New York, NY 10104-3800

Tel. 212-218-2100